JP2009516747A5 - - Google Patents

Download PDF

Info

Publication number
JP2009516747A5
JP2009516747A5 JP2008542425A JP2008542425A JP2009516747A5 JP 2009516747 A5 JP2009516747 A5 JP 2009516747A5 JP 2008542425 A JP2008542425 A JP 2008542425A JP 2008542425 A JP2008542425 A JP 2008542425A JP 2009516747 A5 JP2009516747 A5 JP 2009516747A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
independently
carbocyclyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008542425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009516747A (ja
JP5256042B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/045151 external-priority patent/WO2007062093A2/en
Publication of JP2009516747A publication Critical patent/JP2009516747A/ja
Publication of JP2009516747A5 publication Critical patent/JP2009516747A5/ja
Application granted granted Critical
Publication of JP5256042B2 publication Critical patent/JP5256042B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008542425A 2005-11-22 2006-11-21 癌の処置のための併用療法 Expired - Fee Related JP5256042B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73891905P 2005-11-22 2005-11-22
US60/738,919 2005-11-22
PCT/US2006/045151 WO2007062093A2 (en) 2005-11-22 2006-11-21 Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor

Publications (3)

Publication Number Publication Date
JP2009516747A JP2009516747A (ja) 2009-04-23
JP2009516747A5 true JP2009516747A5 (enExample) 2010-01-14
JP5256042B2 JP5256042B2 (ja) 2013-08-07

Family

ID=37994504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008542425A Expired - Fee Related JP5256042B2 (ja) 2005-11-22 2006-11-21 癌の処置のための併用療法

Country Status (5)

Country Link
US (1) US8324194B2 (enExample)
EP (1) EP1951242A2 (enExample)
JP (1) JP5256042B2 (enExample)
CA (1) CA2628747C (enExample)
WO (1) WO2007062093A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089294A2 (en) 2003-04-04 2004-10-21 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
EP1622569B1 (en) 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
EP2264030A1 (en) * 2003-10-17 2010-12-22 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
US7910108B2 (en) 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
SI2242771T1 (sl) 2007-12-14 2013-09-30 Bristol-Myers Squibb Company Vezane molekule k humanemu ox40 receptorju
US20100332417A1 (en) * 2009-06-02 2010-12-30 Targeted Molecular Diagnostics, Llc Methods for the detection and quantitation of the p95 component of her2/neu (erbb2)
WO2011083391A2 (en) 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
HRP20170411T1 (hr) 2012-03-02 2017-06-16 Genentech, Inc. Amido spirocilični amidni i sulfonamidni derivati
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
PL2844282T3 (pl) 2012-05-04 2019-11-29 Pfizer Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
RS57840B1 (sr) 2013-03-18 2018-12-31 Biocerox Prod Bv Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
US20160060288A1 (en) * 2013-04-18 2016-03-03 Xi'anlibang Pharmaceutical Technology Co., Ltd. Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
EP4149547A4 (en) 2020-05-13 2024-08-14 Adagene AG Compositions and methods for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
JP2004508334A (ja) * 2000-09-08 2004-03-18 フアルマシア・イタリア・エツセ・ピー・アー 化学予防剤としてのエクセメスタン
EP1377298B1 (en) 2001-01-26 2006-08-30 Pfizer Italia S.r.l. Exemestane for treating hormono-dependent disorders
WO2004089294A2 (en) * 2003-04-04 2004-10-21 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
EP1622569B1 (en) * 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
EP2264030A1 (en) * 2003-10-17 2010-12-22 Incyte Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
WO2005117882A2 (en) * 2004-04-20 2005-12-15 Incyte Corporation Hydroxamic acid derivatives as metalloprotease inhibitors
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases

Similar Documents

Publication Publication Date Title
CA2628747A1 (en) Combinations of hormone therapy agents and metalloprotease inhibitors for the treatment of cancer
US6291505B1 (en) Estrogen receptor modulators
US7186838B2 (en) Fluorinated 4-azasteroid derivatives as androgen receptor modulators
CN101243052B (zh) 螺旋结构12定位的非甾族抗雄激素物质
JP5595402B2 (ja) アンドロゲン受容体モジュレーターとしての新規イミダゾリジン化合物
US10730856B2 (en) Benzimidazole derivatives as EP4 ligands
CN104428309B (zh) 3-取代的雌甾-1,3,5(10),16-四烯衍生物、其制备方法、包含其的药物制剂及其用于制备药物的用途
US20100331333A1 (en) Imidazo [1,2-B] Pyridazine Compounds
CN105873917B (zh) 含有吡啶基部分的非甾体类抗雄激素和选择性雄激素受体调节剂
US10344034B2 (en) Pyrazolopyrimidone or Pyrrolotriazone derivatives, method of preparing same, and pharmaceutical applications thereof
CN101175747A (zh) 作为选择性雄激素受体调节剂的取代的n-芳基吡咯烷化合物
EP1581217A1 (en) Carbonylamino-benzimidazole derivatives as androgen receptor modulators
JP4607860B2 (ja) 腫瘍阻害作用を有する抗−アンドロゲン性ピロリジン
JP2002522425A (ja) エストロゲンレセプターモジュレーターとしての置換イソオキサゾール
JP2012502975A (ja) 治療において有用なアミド化合物
US20100324073A1 (en) Pyrazolo [1,5-A] Pyrimidine Compounds
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
Nakagawa et al. Progesterone receptor antagonists with a 3-phenylquinazoline-2, 4-dione/2-phenylisoquinoline-1, 3-dione skeleton
KR102606375B1 (ko) N-방향족 아미드류 화합물 및 이의 제조 방법과 용도
ES2264032T3 (es) Derivados de n-fenilamino-1h-imidazol como inhibidores de la aromatasa.
US6737433B1 (en) 1-N-phenylamino-1H-imidazole derivatives as aromatase inhibitors and pharmaceutical compositions containing them
HK1223609B (en) Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
JP2007204371A (ja) 複素環誘導体
OA12973A (en) 1-N-phenylamino-1H-imidazole derivatives as aromatase inhibitors.